Go Makimoto

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani et al. · Cancer Science · 2021 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Kiichiro Ninomiya, Kadoaki Ohashi, Go Makimoto et al. · Scientific Reports · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY)

Kiichiro Ninomiya, Tae Hata, Hiroshige Yoshioka et al. · CHEST Journal · 2019 · 39 citations

Medicine, Oncology, Pathology +14

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

Satoru Senoo, Takashi Ninomiya, Go Makimoto et al. · Internal Medicine · 2018 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities

Hisao Higo, Toshio Kubo, Satoko Makimoto et al. · Japanese Journal of Clinical Oncology · 2019 · 31 citations

Medicine, Oncology, Radiology +14